Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC)). Background:…The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial
Objective: To assess the therapeutic effect of DL-3-n-butylphthalide on cognitive impairment associated with Parkinson’s disease (PD). Background: PD associated cognitive impairment are attracting attention because…Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain
Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease
Objective: The aim of this observational study for PD patients treated with foslevodopa/foscarbidopa(LDP/CDP) is to evaluate clinical characteristics, therapeutic efficacy and safety, and to determine…The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases
Objective: Demonstration of the anti-prionic MoA for α-synuclein in vitro, PoC in vivo, as well as ex vivo. Background: Neurodegenerative protein-misfolding diseases, like Alzheimer’s (AD)…Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…Rora deficiency aggravates dopamine neurons loss via reducing NAD+ level in Parkinson’s disease
Objective: To investigate the mechanism by which retinoic acid-related orphan receptor alpha(RORα) regulates NAD+ levels to dopamine neuronal degeneration in Parkinson’s Disease (PD). Background: PD is an age-related degenerative…Exercise Mitigates DNA Methylation Changes at cg17274742 Associated with the Circadian Gene Variant PER2 rs2304672: A Biobank Analysis
Objective: This research aims to dissect the influence of physical activity and circadian rhythms on neuroinflammation and neurodegenerative disease progression, focusing on Parkinson's Disease (PD).…Distinct Gut Microbiome in Parkinson’s disease Based on the Presence of Premotor Rapid-Eye Movement Sleep Behavior Disorders: Exploring the Alpha-synuclein
Objective: We aim to investigate the microbiome composition and functional profiles in Parkinson’s disease (PD) patients with and without premotor rapid eye movement sleep behavior…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 436
- Next Page »